UNIVERSITY OF LEEDS

This is a repository copy of *The CABI Trial: an Unblinded Parallel Group Randomised Controlled Feasibility Trial of Long-Course Antibiotic Therapy (28 Days) Compared with Short Course (≤ 10 Days) in the Prevention of Relapse in Adults Treated for Complicated Intra-Abdominal Infection*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/169977/

Version: Accepted Version

Article:

Ahmed, S, Brown, R, Pettinger, R et al. (3 more authors) (2020) The CABI Trial: an Unblinded Parallel Group Randomised Controlled Feasibility Trial of Long-Course Antibiotic Therapy (28 Days) Compared with Short Course (≤ 10 Days) in the Prevention of Relapse in Adults Treated for Complicated Intra-Abdominal Infection. Journal of Gastrointestinal Surgery. ISSN 1091-255X

https://doi.org/10.1007/s11605-020-04545-2

White Rose
university consortium
Universities of Leeds, Sheffield & York

eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/

1 **Title**: The CABI trial: An unblinded parallel group randomised controlled feasibility trial of long

2 course antibiotic therapy (28 days) compared to short course (≤10 days) in the prevention of

3 relapse in adults treated for Complicated intra-ABdominal Infection.

4 **Author names**: Shadia Ahmed[1,2], Rory Brown,[1] Richard Pettinger,[1] Armando Vargas-

5 Palacios[2], Dermot Burke[1,2], Andrew Kirby[1,2]

6 **Author Affiliations**:

7 [1]Leeds Teaching Hospitals NHS Trust, Leeds, LS1 3EX, UK

8 [2]University of Leeds, Leeds LS3 1EX, UK

9 **Corresponding author**: Shadia Ahmed. Microbiology Department, Old Medical School,

10 Leeds General Infirmary, Leeds, LS1 3EX. Tel: 0044 113 3923929. E-mail:

11 shadiaahmed@nhs.net

12 ORCID IDs: Shadia Ahmed (0000-0002-5841-2804), Rory Brown (0000-0002-3085-0319),

13 Richard Pettinger (0000-0001-6820-1894), Armando Vargas-Palacios (0000-0002-6503-

14 0134), Dermot Burke (0000-0002-4342-7464) and Andrew Kirby (0000-0002-2440-9316).

15 **Author Contributions**: All authors contributed to the study conception, design, material

16 preparation, data collection and analysis. The first draft of the manuscript was written by

17 Shadia Ahmed and all authors commented on previous versions of the manuscript. All authors

18 read and approved the final manuscript.

21

22

23

24   **Abstract**

25   **Purpose**: Relapse after complicated intra-abdominal infection (cIAI) remains common after

26   treatment. The optimal antibiotic treatment duration for cIAIs is uncertain, especially in cases

27   where source control is not achieved. We hypothesised that in patients with cIAIs, regardless

28   of source control intervention, there would be a lower relapse rate with long course antibiotics

29   (28 days) compared to short course (≤10 days). We piloted a trial comparing ≤10 days to 28

30   days antibiotics for cIAI.

31   **Methods:** A randomised controlled unblinded feasibility trial was conducted. Eligible

32   participants were adult patients with a cIAI that was diagnosed ≤ 6 days prior to screening.

33   Randomisation was to long course (28 days) or short course (≤10 days) antibiotic therapy.

34   Choice of antibiotics was determined by the clinical team. Participants were followed up for 90

35   days. Primary outcomes were willingness of participants to be randomised and feasibility of

36   trial procedures.

37   **Results:** In total, 172 patients were screened, 84/172 (48.8%) were eligible and 31/84 (36.9%)

38   were randomised. Patients were assigned to either the short course arm (18/31, 58.0%) or the

39   long course arm (13/31,41.9%). One patient in the short course arm withdrew after

40   randomization. In the short course arm, 4/17 (23.5%) were treated for a cIAI relapse vs 0/13

41   (0.0%) relapses in the long course arm. Protocol violations included deviations from protocol

42   assigned antibiotic duration and interruptions to antibiotic therapy.

43   **Conclusions:** This feasibility study identified opportunities to increase recruitment in a full

44   trial. This study demonstrates completion of a randomized controlled trial to further evaluate

45   the optimum antibiotic duration for cIAIs is feasible.

46   **Trial registration:** NCT03265834.

47   **Key words**: Antibiotic; Complicated intra-abdominal infection; duration; trial

48

Introduction

Complicated intra-abdominal infections (cIAIs) extend beyond the hollow viscus of origin into the peritoneal space and are associated with either abscess formation or peritonitis [1]. They are heterogeneous in aetiology and include spontaneous infections arising from a perforated intra-abdominal viscus, and post-operative infections. Despite the varied origin of these infections, there are similar management strategies that centre on source control, e.g. drainage of intra-abdominal fluid collections, and administration of antibiotic therapy. These infections are challenging to manage, in part due to the varied pathology that causes them, and are associated with significant morbidity and mortality [2, 3]. Despite this burden of disease, there is little clinical evidence on which to base antibiotic treatment. At present there have been two trials into antibiotic durations for cIAI. The STOP-IT trial [4], which compared 4 vs. 8 days (median durations) found that longer durations significantly reduced the time until relapse (p=<0.001). The DURAPOP trial compared 8 to 15 days duration and found a lower rate of clinical failure in patients with the longer course antibiotics, 24% (28/120) with 8 days and 14% (16/116) with 15 days (p=0.54) [5]. Given that there remains a high relapse rate, it has been suggested that longer courses of antibiotics may reduce relapse of cIAIs[6]. In the UK, for serious infections (brain abscess, mastoiditis, septic arthritis, osteomyelitis, lung abscess, endocarditis, and prostatitis) which have a high risk of relapse and associated mortality, microbiologists often recommend up to and beyond four weeks of antibiotic therapy. This approach has not yet been investigated in a RCT for cIAIs. **Furthermore, around 30% of patients in England and Scotland, do not undergo source control procedures [7] and thus far there have been no trials evaluating antibiotic duration in this patient group.** We therefore hypothesise that in patients with cIAIs, regardless of source control intervention; there will be a lower relapse rate when treated with 28 days of antibiotics compared to ≤10 days of antibiotics.

Materials and Methods

Trial design: An unblinded parallel group randomised controlled feasibility trial comparing long course (28 days) to short course (≤10 days) antibiotic therapy in patients with cIAI was carried out. This feasibility trial was approved by the Yorkshire and Humber (Leeds–East)

78   Research Ethics Committee, UK (16/YH0453) (ClinicalTrials.gov Identifier: NCT03265834).

79   The study is reported according to the CONSORT extension to pilot and feasibility trials, see

80   supplementary material.

81   **Participants**: Participants were eligible if they were aged ≥ 18 years old and had been

82   diagnosed with a cIAI. The diagnostic criteria for a cIAI diagnosis included the presence of

83   both radiological and clinical features consistent with a cIAI, including a fever (temperature of

84   ≥38 ˚C) and a neutrophilia (> 7.5 x 10*9/L) or intra-operative confirmation of an abscess. Any

85   cIAI diagnosed >6 days prior to screening was excluded. Patients were identified either by

86   notification by a member of the patient's clinical team to the research team, or by screening of

87   radiology reports. Participants were excluded if their cIAI was associated with uncomplicated

88   appendicitis, primary complicated appendicitis, pancreatitis, pelvic inflammatory disease,

89   primary (spontaneous) bacterial peritonitis (SBP), continuous ambulatory peritoneal dialysis

90   peritonitis (CAPD peritonitis) and *Clostridium difficile* infection as they were consider distinct

91   conditions with separate management strategies. Patients were recruited from Leeds

92   Teaching Hospitals NHS trust in the United Kingdom between August 2017 and June 2018.

93   The trial was stopped at the end of funding for the trial research staff.

94   **Interventions**: Participants received either ≤ 10 days (short course [SC]) or 28 days (long

95   course [LC]) of antibiotic therapy. The clinical team caring for the patient determined the choice

96   of antibiotic, as the aim was to compare antibiotic prescribing strategies (i.e. short course vs

97   long course) rather than individual drugs or specified combinations of drugs. **The antibiotic**

98   **prescribed was chosen according to the available clinical and microbiological data, in**

99   **conjunction with local antibiotic guidelines, and altered as new results and clinical**

100   **information become available.**

101   **Outcomes**: The primary outcomes were to determine trial feasibility and included: the

102   willingness of participants to be randomised, the willingness of clinicians to allow patients to

103   be recruited, the number of eligible patients and follow up rates. Additionally, data on clinical

104   objectives that would be the primary and secondary objectives for a definitive study following

105   on from the feasibility study were collected in order to determine the feasibility of collecting

106   this information. These clinical objectives included rate of relapse, mortality, total days of

107　antibiotic consumption, all infections within 90 days of cIAI diagnosis, length of hospital stay

108　and number of source control procedures required. Participants were followed up for 90 days

109　and outcomes assessed at 30 days and 90 days post cIAI diagnosis (via telephone

110　consultation or inpatient review).

111　**Relapse of cIAI was defined as relapse of infection occruing after surgical and antibiotic**

112　**therapy to manage the primary CABI had been considered successful (as demonstrated**

113　**by antibiotics being stopped and no further source control procedures planned).**

114　**Relapse of cIAI included both definite and probable cases. A definite case was defined**

115　**as cIAI relapse with a combination of radiological and clinical features consistent with**

116　**CABI including a fluid collection, a temperature of ≥38 degrees and a neutrophilia**

117　**(neutrophil count > 7.5 x 10*9/L) or intra-operative confirmation of an abscess. Probable**

118　**cIAI relapse included cases where there was either absence of radiological imaging or**

119　**radiological features inconsistent with a cIAI, but where no other source of infection**

120　**was identified, and the patient was managed for a relapsed cIAI.**

121　Quality of life was assessed with the European Quality of Life–5 Dimensions 3-Level

122　questionnaire (EQ-5D-3L) and the EQ-5D visual-analogue scale (EQ-5D VAS) at baseline,

123　day 30, day 90 and at the time of cIAI relapse.

124　**Sample size**: Given that this was a feasibility study, no formal sample size calculation was

125　performed and a maximum patient recruitment target of 60 patients was set [8].

126　**Randomisation**: Patients in each intervention arm were stratified into two groups; post-

127　operative cIAIs (cIAI within 90 days of surgery) and non post-operative cIAIs (primary cIAIs).

128　Simple randomisation with a 1:1 allocation ratio was then used to allocate patients.

129　**Sequence generation**: A web based sequence generator was used to generate an

130　unpredictable allocation sequence (https://www.random.org/sequences/).

131　**Allocation concealment**: An independent person outside of the research team transferred

132　the sequence into sealed envelopes, which were then accessed after trial enrolment to

133　allocate participants to a treatment arm.

134 **Implementation**: Patient's allocation was determined by a trial researcher (SA, RA & RB)

135 after a patient had given their consent.

136 **Blinding**: Patients, researchers and clinicians were not blinded to the treatment allocation.

137 **Statistical methods**: Descriptive statistics **were** used to report outcomes and baseline

138 characteristics. Continuous data are summarised as medians and interquartile ranges (IQR)

139 and categorical data were summarised as proportions (percentage). For clinical outcome

140 analysis, intention to treat analysis was completed. Sub-group analysis of post-operative cIAIs

141 vs non post-operative cIAIs was also completed. All analyses were conducted using the

142 statistical package SPSS (IBM SPSS Statistics for Windows, Version 23.0, IBM Corp).

143 **Protocol amendments**: One protocol amendment was made and implemented during the

144 study and the substantial changes included the following: The exclusion of any patients who

145 had a cIAI in the previous one year was changed to three months to allow inclusion of more

146 patients with cIAIs. The definition of cIAI was amended to include patients with fever prior to

147 admission and patients who have evidence of purulent peritonitis intra-operatively. An

148 amendment that was approved but not implemented was for the recruitment of patients via

149 consultee consent.

150 **Results**

151 **Participant flow:** From August 2017 to June 2018, 172 patients were assessed for eligibility,

152 84/172 (48.8%) were eligible for enrolment and 31/84 (36.9%) were enrolled and randomised.

153 Eight-eight patients were ineligible, of whom 42 (47.7%) were being treated for a cIAI but did

154 not have a fever and a raised neutrophil count and 14 (15.9%) patients were ineligible because

155 they had had >6 days of antibiotics for their cIAI. Of the 53/84 (63.1%) patients who were

156 eligible but not enrolled; 32 declined participation (Table 1),13 were either discharged or had

157 antibiotics discontinued before consent or approach by the research team, two were not

158 enrolled at the request of the treating surgeon, two died prior to approach and four were not

159 recruited for other reasons (one patient was non-english speaking, one was breastfeeding,

160 one was due to undergo major surgery for another indication and one was unabe to be

161 followed up due to travel outside of the continent). Patients who declined to participate in the

162 study were more likely to have had a HDU/ICU admission (13.3% of patients who consented

11

163 to participate had a HDU/ICU admission vs 25.0% of patients who declined to participate).

164 Reasons for declining to participate included a preference for an antibiotic duration (4/32),

165 feeling too unwell (4/32), concern over adverse events (3/32), but most commonly no reason

166 was given (20/32). One patient withdrew from the study after randomisation, the remaining

167 30/31 randomised patients were followed up for the complete study period. Participant flow is

168 outlined in the Consolidated Standards of Reporting Trials (CONSORT) flow diagram in Figure

169 1.

170 **Protocol adherence**: Participants were deemed to have received allocated treatment if in the

171 SC arm they received < 10 days (+1) and in the LC arm 28 days (+/- 1). In the SC treatment

172 arm, 4/17 (24%) patients continued antibiotics for longer than the allocated duration; two

173 received 14 days and two received 12 days treatment. Whereas, 5/13 (38%) patients in the

174 LC treatment arm did not receive the allocated treatment duration of antibiotics; one patient

175 discontinued early at day 20 due to a serious adverse event (SAE) from co-amoxiclav

176 (deranged liver function tests), three patients had their antibiotics stopped early (days 4, 5 and

177 15) inadvertently by members of the clinical team who were unaware of treatment allocation

178 and one patient continued antibiotics for 30 days.

179 **Baseline data**: The baseline characteristics of patients enrolled in the study are summarised

180 in Table 2. Characteristics of patients in each arm of the study were comparable apart from

181 the number of patients with post-operative cIAIs, which was higher in the short course arm

182 (59% vs 31%).

183 **Numbers analysed, Outcomes and Estimations**

184 **Intention to treat (ITT) analysis:** Overall 4/30 (13.3%) patients had either a definite or

185 probable cIAI relapse, all of whom were randomised to receive short course antibiotics.

186 Only one patient died during the study, this patient was randomised to receive 28 days of

187 antibiotics however treatment was stopped early on day four of treatment. The overall hospital

188 stay was 8 days (IQR 4.5-11) in patients who had long course antibiotics and 9 days (IQR 4.5-

189 31) in patients who had short course antibiotics. A higher proportion of patients in the SC arm

190 had other infection diagnoses during the follow up period compared to the LC arm (6/17

11

191 [35.3%] vs 1/13 [7.9%]). Clinical outcomes are shown in Table 3, and characteristics by

192 presence or absence of relapse are shown in Table 4.

193 **Sub group analysis**: In total, 14/30 (46.7%) patients had a post-operative cIAI (cIAI within 90

194 days of abdominal surgery). Of these, four received long course antibiotics and ten short

195 course antibiotics. Out of the four patients who had a cIAI relapse, three had post-operative

196 cIAIs.

197 **Quality of life analysis:** In total, 26/30 participants completed EQ-5D-3L and EQ-VAS

198 questionnaires for all time points. For the baseline assessments, data on 1/30 EQ-5D-3L and

199 2/30 EQ-VAS were missing. One patient died before day 30 assessments took place, and 1/29

200 day 30 EQ-VAS and 1/29 day 90 EQ-VAS were missing. All four patients who had a cIAI

201 relapse completed a EQ-5D-3L and EQ-VAS questionairres at the time of cIAI relapse.

202 **Source control procedures: Overall, eight patients did not undergo source control**

203 **procedures. Six patients in the SC arm did not under go source control: three of these**

204 **patients had post-operative cIAIs, two had complicated diverticular disease and one**

205 **had perforated peptic ulcer. Two patients in the LC arm did not undergo source control;**

206 **both had cIAI due to complicated diverticulitis.**

207 **Of the 11/13 patients who had source control in the LC arm, three had percutaneous**

208 **drainage and eight had surgical procedures (four had resection with anastomosis or**

209 **closures and four had resection with proximal diversion. In the SC arm, 7/17 had**

210 **percuteous drainage and 4/17 had surgical source control (one had surgical drainage,**

211 **one had closure of perforation with a washout and two had surgical resection with**

212 **proximal diversion).**

213 **Antibiotic treatment**: The median antibiotic treatment duration was 9 days (IQR 7.5 - 11.5)

214 in the group of patients receiving SC antibiotics and 28 days (IQR 17.5 - 28.0) in the group

215 receiving LC antibiotics. The most frequently used intravenous antibiotic regimen was

216 cefuroxime and metronidazole, which was used in 14/30 (46.7%) participants (6 patients in

217 LC arm and 8 patients in SC). Piperacillin-tazobactam was the second commonest antibiotic

218 regimen and used in 7/30 (23.3%) patients (6 patients in the SC and 1 in the LC arm).

219 Amoxicillin plus clavulanic acid was the most frequently used oral regimen; 13/30 (43.3%)

220 patients (6 in the SC arm and 7 in the LC arm). Two patients out of the 13 patients in the SC

221 arm had interruptions to their antibiotic course (antibiotics stopped and restarted), this led to

222 one patient receiving antibiotics for longer than the assigned duration. Overall, seven patients

223 had their initial antibiotic regimen altered due to the presence of resistant organisms; 3/11

224 (27.2%) in the LC arm and 4/16 (25.0%) in the SC arm.

225 **Harms**: One SAE related to the study occurred in a patient allocated to receive LC who

226 developed deranged liver function tests (LFTs) which normalised after cessation of antibiotics.

227 Other SAEs that occurred which were unrelated to the study procedures included: small bowel

228 obstruction secondary to adhesions, stroke, acute kidney injury, episode of uncomplicated

229 diverticulitis and pulmonary embolus. **There were no episodes of *Clostridium difficile***

230 **infection.**

231 **Discussion**

232 The optimal antibiotic treatment strategy for cIAIs remains uncertain especially in cases where

233 it is not feasible to perform source control. To date there have been two RCTs which have

234 evaluated antibiotic duration for cIAIs where source control has been achieved. The STOP IT

235 trial reported that in patients who had adequate source control, short course antibiotic therapy

236 (median 4 days) was as effective as long course therapy (median 8 days) [4]. The DURAPOP

237 trial assessed antibiotic duration for intensive care patients and compared eight days to fifteen

238 days of antibiotic therapy [5]. The primary outcome was antibiotic free days within the 45 days

239 after source control and results favoured 8 days of treatment (median number of antibiotic-

240 free days 15 [6-20] vs 12 [6-13] days). However in both trials clinical failure was common (15-

241 24%). One reason for relapse of cIAI may be that antibiotic treatment may not have been given

242 for long enough to eradicate bacteria from, what should be, a sterile intra-abdominal cavity.

243 Thus, long course antibiotic therapy may reduce the rate of cIAI relapse .

244 This RCT of short course (≤ 10 days) or long course (28 days) antibiotic therapy for cIAIs was

245 designed to determine the feasibility of conducting a definitive RCT. An adequate proportion

246 (36.7%) of eligible patients were enrolled which suggests that it would be feasible to enrol

247 patients into such a definitive trial. Additionally, with the exception of two cases, clinicians were

248 willing for patients to be recruited and patients were able to successfully complete follow-up.

249 Whilst our recruitment target of 60 patients was not reached, we recruited sufficient patients

250 to be able to determine trial feasibility.

251 During the trial there were minimal data missing on primary and secondary outcome

252 measures, with the exception of EQ-5D questionnaires. However, the rate of missing data was

253 low, therefore using EQ-5D questionnaires to calculate QALYs for economic evaluation will

254 still be a feasible in a definitive trial. **Overall, protocol adherence was 70%, in keeping with**

255 **other trials that dictate antibiotic duration: protocol adherence was 82% in the**

256 **experimental group & 72.7% in the control group in the STOP IT trial, 79% & 82% in the**

257 **two arms in the DURAPOP trial** [4, 5]. Non adherence was mostly associated with antibiotics

258 durations being outside accepted ranges, extending these beyond 24 hours would increase

259 adherence and not detract from the overall treatment allocations.

260 We identified aspects of the protocol that reduced recruitment. The definition of cIAI used in

261 this study was more inclusive than recommended definitions as it allowed surgeons to make

262 a diagnosis of cIAI without operative evidence, thus allowing inclusion of patients who do not

263 undergo a source control procedure [9]. However, the definition used for cIAI in this trial

264 excluded 48% of patients who were treated for cIAI because they did not have both a recorded

265 fever (≥ 38°C) and a neutrophilia (>7.5 10*9/L). In a definitive trial, a more pragmatic definition

266 should be adopted to ensure evidence is gained for a more representative population of

267 patients treated for cIAI. Additionally, it was noted **other infections e.g. urinary tract or**

268 **respiratory tract infection,** not including cIAI relapses, were common, and consideration to

269 these being included within a primary outcome measure in a definitive trial would be needed.

270 **This study was not designed to detect a clinically significant difference in the**

271 **secondary outcomes, however we found that relapses predominantly occurred in**

272 **patients who had post-operative cIAIs who received short course antibiotics. Thus,**

273 **supporting further research into our hypothesis that longer antibiotic durations may**

274 **reduce relapse rates.**

275 Complicated intra-abdominal infections continue to be associated with significant morbidity

276 and mortality. This trial demonstrates the feasibility of a substantive RCT to further investigate

277 antibiotic durations for the management of cIAIs.

282 **Compliance with Ethical Standards**

283 **Conflicts of interest**: The authors declare that they have no conflict of interest.

284 **Ethical approval**: All procedures performed in studies involving human participants were in

285 accordance with the ethical standards of the institutional and/or national research committee

286 and with the 1964 Helsinki declaration and its later amendments or comparable ethical

287 standards.

288 **Informed consent**: Informed consent was obtained from all individual participants included in

289 the study.

290 **Data availability**: The datasets generated during and analysed during the current study are

291 available from the corresponding author on reasonable request.

292

293

294

295

296

297

References

298   1.   Solomkin, J.S., et al., *Diagnosis and management of complicated intra-*
299   *abdominal infection in adults and children: guidelines by the Surgical Infection*
300   *Society and the Infectious Diseases Society of America.* Clin Infect Dis, 2010.
301   **50**(2): p. 133-64.
302   2.   Brun-Buisson, C., et al., *Incidence, risk factors, and outcome of severe sepsis*
303   *and septic shock in adults. A multicenter prospective study in intensive care*
304   *units. French ICU Group for Severe Sepsis.* JAMA, 1995. **274**(12): p. 968-74.
305   3.   DeFrances, C.J., K.A. Cullen, and L.J. Kozak, *National Hospital Discharge*
306   *Survey: 2005 annual summary with detailed diagnosis and procedure data.*
307   Vital Health Stat 13, 2007(165): p. 1-209.
308   4.   Sawyer, R.G., et al., *Trial of short-course antimicrobial therapy for*
309   *intraabdominal infection.* N Engl J Med, 2015. **372**(21): p. 1996-2005.
310   5.   Montravers, P., et al., *Short-course antibiotic therapy for critically ill patients*
311   *treated for postoperative intra-abdominal infection: the DURAPOP*
312   *randomised clinical trial.* Intensive Care Med, 2018. **44**(3): p. 300-310.
313   6.   Wenzel, R.P. and M.B. Edmond, *Antibiotics for abdominal sepsis.* N Engl J
314   Med, 2015. **372**(21): p. 2062-3.
315   7.   Ahmed, S.C.C., *Clinical Management of Complicated Intra-abdominal*
316   *Infections in the United Kingdom*, in *28th European Congress of Clinical*
317   *Microbiology & Infectious Diseases.* 2018: Madrid, Spain.
318   8.   Billingham, S.A., A.L. Whitehead, and S.A. Julious, *An audit of sample sizes*
319   *for pilot and feasibility trials being undertaken in the United Kingdom*
320   *registered in the United Kingdom Clinical Research Network database.* BMC
321   Med Res Methodol, 2013. **13**: p. 104.
322   9.   Nystrom, P.O., et al., *Proposed definitions for diagnosis, severity scoring,*
323   *stratification, and outcome for trials on intraabdominal infection. Joint Working*
324   *Party of SIS North America and Europe.* World J Surg, 1990. **14**(2): p. 148-58.

325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346

Tables and figures

Table 1. Characteristics of patients who consented to participate and those who declined

	Consented (n 31)	Declined (n 32)
Age (years)	61.0 (45.0-72.0)	60.5 (48.3-79.3)
Females	11/31 (35.5%)	17/32 (53.1%)
Charlson score	4 (1-5)	4 (1.3-5)
HDU/ICU Admission	4/31 (12.9%)	8/32 (25.0%)
Post-operative infection	14/31 (45.2%)	13/32 (40.6%)
Presence of a perforated viscus	13/31 (41.9%)	13/32 (40.6%)
Data are median (IQR) or n/total (%)		

Table 2. Baseline characteristics of patients in each study arm

	Long course group, n=13	Short course group, n=17
Age (years)	60.0 (46.5-74.5)	63.0 (46.0-72.0)
Female	5/13 (38.5%)	6/17 (35.3%)
Charlson score	4 (1.5-8.5)	4 (1-5)
HDU/ICU Admission	2/13 (15.4%)	2/17 (11.8%)
Post-operative infection	4/13 (30.8%)	10/17 (58.8%)
Perforated viscus	7/13 (53.8%)	5/17 (29.4%)
Presence of a collection	8/13 (61.5%)	14/17 (82.4%)
Anastomotic leak	1/13 (7.7%)	4/17 (23.5%)
Site of cIAI		
Appendix	0/13 (0%)	1/17 (5.9%)
Biliary	1/13 (7.7%)	0/17 (0%)
Colon	5/13 (38.5%)	7/17 (41.2%)
Small bowel	3/13 (23.1%)	1/17 (5.9%)
Other	4/13 (30.8%)	7/17 (41.2%)
Gastro-oesophageal	0/13 (0%)	1/17 (5.9%)
Baseline health status°^	35.0 (20.0-50.0)	30.0 (20.0-40.0)
NEWS* at diagnosis	3.0 (2.0-4.0)	3.0 (1.5-6.0)
C-reactive protein (mg/L) at diagnosis	220.0 (88.5-276.0)	218.0 (124.0-290.0)
Neutrophil count (10*9/L) at diagnosis	13.0 (9.2-15.2)	12.8 (9.4-19.2)
Temperature at diagnosis °C)	38.3 (38.2-38.5)	38.3 (37.8-38.7)
Source control procedure		
Percutaneous drainage	3/13 (23.1%)	7/17 (41.2%)
Surgical	8/13 (61.5%)	4/17 (23.5%)
Nil	2 (15.4%)	6/17 (35.3%)
Samples° sent for culture	11/13 (84.6%)	16/17 (94.1%)
Antibiotic regimen altered due to drug resistant bacteria	3/11 (27.2%)	4/16 (25.0%)
Data are median (IQR) or n/total (%).		

°Measured by patient self-reported rating (EQ5D-VAS) on own overall health, scale from 0 (worst possible health) to 100 (best possible health). *National Early Warning Score. ^data missing in 1/13 in LC arm and 1/17 in SC arm. ∞Samples include blood cultures or pus cultures obtained intra-operatively/percutaneously

Table 3. Clinical outcomes (ITT analysis) at 90 days

	Total	Long course group	Short course group
Antibiotic duration (days) for cIAI	11.5 (8.0-28.0)	28 (17.5-28.0)	9 (7.5-11.5)
Relapse	4/30 (13.3%)	0 (0%)	4/17 (23.3%)
Death	1/30 (3%)	1/13 (7.7%)	0/17
Total antibiotic consumption (days) within 90 days of cIAI diagnosis	19 (9.8-28.0)	28 (17.5-30.0)	15 (8.5-26.0)
Length of stay (days) following cIAI diagnosis	8.5(4.8-17.8)	8.0 (4.5-11.0)	9.0 (4.5-31.0)
Number of source control procedures required for the management of cIAI	1 (0.8-1)	1 (1-1)	1 (0-1)
Data are median (IQR) or n/total (%)			

Table 4.

	Relapse (n = 4)	No relapse (n = 26)
Age (years)	65.5 (49.5-83.0)	61.0 (45.8-72.0)
Female	3/4 (75%)	8/26 (30.8%)
Median Charlson score (IQR)	4.0 (1.5-8.0)	4.0 (1.0-5.3)
Post-operative infection	3/4 (75.0%)	11/26 (42.3%)
Presence of a perforated viscus	1/4 (25%)	11/26 (42.3)
Presence of a collection(s)	3/4 (75%)	19/26 (73.0%)
Anastomotic leak	1/4 (25%)	4/26 (15.4%)
NEWS* at diagnosis	3.0 (0.5-6.8)	3.0 (2.0-5.3)
Source control procedure		
Percutaneous drainage	1/4 (25%)	7/ 26 (26.9%)
Surgical	2/4 (50%)	9/26 (34.6%)
Nil	1/4 (25%)	10/26 (38.5%)
Site of cIAI		
Appendix	0/4 (0%)	1/26 (3.8%)
Biliary	0/4 (0%)	1/26 (3.8%)
Colon	2/4 (50.0%)	10/26 (38.5%)
Small bowel	1/4 (25%)	3/26 (11.5%)
Other	1/4 (25%)	10/26 (38.5%)
Gastro-oesophageal	0/4 (0%)	1/26 (3.8%)
Antibiotic regimen altered due to presence of resistance	2/4 (50%)	5/26 (19.2%)
Data are median (IQR) or n/total (%). * National Early Warning Score		

Characteristics of patients who had a cIAI relapse

Enrolment

Assessed for eligibility (n= 172)

Excluded (n= 141)
- Not meeting inclusion criteria (n= 88)
- Declined to participate (n= 32)
- Clinician request (n=2)
- Discharged or antibiotics stopped before approach/consent (n=13)
- Other reasons (n=4)
- Patient died before approach/consent (n=2)

Randomised (n= 31)

Allocation

Allocated to short course (n= 18)
- Received allocated intervention (n=14)
- Did not receive allocated intervention (n=4)
  - Continued antibiotics > 11 days (n=4)

Allocated to long course (n=13)
- Received allocated intervention (n=8)
- Did not receive allocated intervention (n= 5)
  - Stopped due to AE (n=1)
  - Stopped early by clinical team (n=3)
  - Continued antibiotics > 29 days (n=1)

Follow-Up

Lost to follow-up (n= 1 withdrew)

Lost to follow-up (n= 0)

Analysis

Intention to treat analysis (n=17)
- 3/17 probable relapse & 1/17 definite relapse
- 0/17 died

Intention to treat analysis (n=13)
- 0/13 relapses
- 1/13 died

351

352   Figure 1. Participant enrolment, allocation, follow-up and analysis

353

354